Annovis Bio, Inc. (ANVS) stock
ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.74−0.01 (-0.91%)
Close on Nov 17, 2026Market cap $31.66MP/E –Yield –
Annovis Bio r&d expenses
Research and development expenses are spending on new products and technology.
Annovis Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $43.77M, up 145.1% year over year. For fiscal 2025 it was $25.22M, up 26.1% from the year before. The highest annual figure on record is $38.79M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.22M | +26.1% |
| FY2024 | Dec 31, 2024 | $20.00M | -48.5% |
| FY2023 | Dec 31, 2023 | $38.79M | +134.9% |
| FY2022 | Dec 31, 2022 | $16.52M | +94.8% |
| FY2021 | Dec 31, 2021 | $8.48M | +177.6% |
| FY2020 | Dec 31, 2020 | $3.05M | +293.4% |
| FY2019 | Dec 31, 2019 | $776.26K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.01M | +132.6% |
| Q1 FY2026 | Mar 31, 2026 | $16.72M | +233.6% |
| Q4 FY2025 | Dec 31, 2025 | $8.75M | +75.1% |
| Q3 FY2025 | Sep 30, 2025 | $6.29M | +133.9% |
| Q2 FY2025 | Jun 30, 2025 | $5.16M | -10.8% |
| Q1 FY2025 | Mar 31, 2025 | $5.01M | -23.1% |
| Q4 FY2024 | Dec 31, 2024 | $5.00M | -43.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.69M | -80.6% |
| Q2 FY2024 | Jun 30, 2024 | $5.79M | -30.0% |
| Q1 FY2024 | Mar 31, 2024 | $6.51M | -16.3% |
| Q4 FY2023 | Dec 31, 2023 | $8.90M | +43.4% |
| Q3 FY2023 | Sep 30, 2023 | $13.84M | +235.6% |
| Q2 FY2023 | Jun 30, 2023 | $8.26M | +104.8% |
| Q1 FY2023 | Mar 31, 2023 | $7.79M | +262.2% |
| Q4 FY2022 | Dec 31, 2022 | $6.21M | +115.3% |
| Q3 FY2022 | Sep 30, 2022 | $4.12M | +198.6% |
| Q2 FY2022 | Jun 30, 2022 | $4.03M | +121.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.15M | -10.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.88M | +104.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.38M | +92.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.82M | +113.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.39M | +3496.3% |
| Q4 FY2020 | Dec 31, 2020 | $1.41M | +85.3% |
| Q3 FY2020 | Sep 30, 2020 | $718.90K | +35612.8% |
| Q2 FY2020 | Jun 30, 2020 | $856.48K | +14080.1% |
| Q1 FY2020 | Mar 31, 2020 | $66.45K | +1003.6% |
| Q4 FY2019 | Dec 31, 2019 | $762.18K | – |
| Q3 FY2019 | Sep 30, 2019 | $2.01K | – |
| Q2 FY2019 | Jun 30, 2019 | $6.04K | – |
| Q1 FY2019 | Mar 31, 2019 | $6.02K | – |
See a number that looks wrong?